SLXNW · Silexion Therapeutics Ltd.

Silexion Therapeutics Corp executed a warrant inducement transaction allowing holders of 1,995,092 existing warrants—comprising Series A and B warrants from the September 2025 public offering and prior inducement warrants from August 2025—to exercise at a steeply reduced price of $0.50 per share, down from original prices of $4.00 and $11.32. This generates approximately $1.0 million in immediate gross proceeds before fees, providing near-term non-dilutive cash inflow critical for a clinical-stage biotech funding general corporate purposes. In exchange, the company issues new warrants for twice the exercised amount (3,990,184 shares), split between longer-term Series C (5 years) and Series D (24 months), both at $0.50 exercise price, exercisable only after shareholder approval and resale registration effectiveness. This structure incentivizes exercise while deferring dilution. H.C. Wainwright & Co. receives standard compensation including 7% cash fees on proceeds and future exercises, plus warrants, aligning interests. Key protections include beneficial ownership caps (4.99%/9.99%), cashless exercise provisions, and fundamental transaction rights with Black-Scholes cash settlement options. The 15-day issuance lockup and 1-year variable rate transaction ban signal commitment to orderly capital markets engagement post-closing, expected May 18, 2026.